maa
mobarakmraheil
mikrobiomedunigiessend
mam
author
contribut
equal
work
abstract
vaccin
function
medic
intervent
prophylact
control
sever
diseas
caus
humantohuman
animaltohuman
transmiss
viral
pathogen
annual
season
influenza
epidem
attack
human
popul
lead
thousand
deathsyear
worldwid
recent
novel
middl
east
respiratori
syndrom
coronaviru
emerg
togeth
two
virus
present
signific
public
health
burden
area
circul
herein
gener
bacteri
outer
membran
vesicl
omv
base
vaccin
present
antigen
stabl
chimer
fusion
protein
haemagglutinin
ha
pandem
influenza
viru
strain
receptor
bind
domain
rbd
middl
east
respiratori
syndrom
coronaviru
merscov
result
show
chimer
antigen
could
induc
specif
neutral
antibodi
strain
lead
protect
immun
mice
effici
neutral
merscov
studi
demonstr
omvsbas
vaccin
present
viral
antigen
provid
safe
reliabl
approach
protect
two
differ
viral
infect
acut
respiratori
infect
among
lead
caus
diseas
mortal
develop
develop
countri
sever
acut
infect
usual
potenti
follow
dissemin
infect
throughout
lower
respiratori
tract
lead
million
human
death
worldwid
year
annual
season
influenza
epidem
attack
human
popul
lead
thousand
deathsyear
worldwid
besid
epidem
world
confront
everi
year
antigen
distinct
pandem
influenza
viru
strain
wide
geograph
distribut
consider
humantohuman
transmiss
result
high
mortal
rate
recent
year
world
challeng
newli
emerg
influenza
viru
iav
infect
potenti
caus
sporad
fatal
human
popul
within
limit
epidem
instanc
highli
pathogen
avian
influenza
virus
hpaiv
low
pathogen
avian
influenza
virus
lpaiv
caus
sporad
human
infect
addit
iav
caus
global
pandem
outbreak
swineorigin
influenza
viru
novel
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
februari
total
laboratoryconfirm
human
case
includ
associ
death
report
global
countri
casefat
rate
major
case
report
arabian
peninsula
specif
saudi
arabia
case
death
casefat
rate
combat
iav
merscov
infect
vaccin
repres
afford
facil
way
protect
devast
epidem
occasion
pandem
howev
despit
signific
effort
develop
safe
effect
vaccin
approv
vaccin
merscov
till
recent
report
also
demonstr
replic
recombin
iav
vaccin
strain
either
embryon
egg
cellcultur
system
allow
viral
adapt
may
affect
antigen
vaccin
therefor
genet
phenotyp
stabl
vaccin
repres
promis
altern
control
iav
merscov
infect
outer
membran
vesicl
omv
natur
spheric
nanoparticl
nm
deriv
gramneg
bacteria
omv
releas
pathogen
nonpathogen
bacteria
highli
immunogen
due
compon
includ
lipopolysaccharid
lp
bacteri
outer
membran
om
protein
lipid
immunogen
toxin
dnarna
periplasmat
cytoplasmat
protein
omv
pathogen
bacteria
commerci
use
induc
specif
antibodi
differ
bacteri
strain
includ
neisseria
meningitidi
serogroup
b
composit
omv
adapt
use
vaccin
platform
via
incorpor
heterolog
antigen
vesicl
engin
approach
advantag
retain
antigen
nativ
conform
ii
enabl
omv
target
specif
immun
respons
iii
provid
multipl
commensur
protein
antigen
singl
product
process
howev
bacteriabas
vaccin
well
explor
deliv
viral
antigen
therefor
engin
stabl
omvsbas
dual
vaccin
merscov
produc
omv
chimer
hemagglutinin
ha
compris
receptor
bind
domain
rbd
merscov
merscov
strain
isol
grown
cell
two
virus
use
prepar
omvsbas
dual
vaccin
inactiv
vaccin
use
posit
control
influenza
construct
plasmid
three
pcr
fragment
encompass
signal
peptid
ha
ii
rbd
merscov
acidpeptid
linker
gsagsag
iii
code
sequenc
ha
amplifi
sequencespecif
primer
tabl
phusion
highfidel
pcr
master
mix
hf
buffer
invitrogen
carlsbad
ca
simultan
ligat
linear
pmpccdb
vector
briefli
pcr
amplif
fragment
phusion
master
mix
forward
revers
primer
ng
accord
templat
dna
mix
reaction
brought
total
volum
use
rnasednasefre
ddh
plasmid
pmphagi
encod
ha
use
templat
dna
plasmid
encod
spike
protein
isol
use
templat
pcr
set
c
min
step
cycl
c
c
c
min
final
extens
step
c
min
three
amplifi
pcr
fragment
load
onto
agarosegel
electrophoresi
separ
purif
three
specif
fragment
done
use
qiaquick
gel
purif
kit
accord
manufactur
qiagen
germani
instruct
purif
three
fragment
digest
correspond
restrict
enzym
shown
tabl
ligat
three
fragment
linear
vector
perform
use
dna
ligas
promega
madison
wi
usa
ad
purifi
fragment
buffer
dna
ligas
linear
vector
mixtur
incub
overnight
c
transform
escherichia
coli
compet
cell
perform
mix
ligat
reaction
bacteri
suspens
invitrogen
ca
usa
subsequ
incub
ice
min
bacteri
cell
subject
heat
shock
c
water
bath
chill
ice
min
ad
soc
media
invitrogen
ca
usa
reaction
tube
rotat
rpm
shake
incub
c
h
incub
time
h
transform
bacteri
suspens
spread
ampicillin
contain
luriabertani
lb
agar
plate
incub
h
c
singl
coloni
select
incub
ml
liquid
lb
h
subsequ
plasmid
isol
correct
e
coli
compet
bacteria
invitrogen
ca
usa
transform
accord
manufactur
instruct
describ
ng
plasmid
individu
coloni
ampicillin
contain
lb
agar
plate
pick
incub
ml
liquid
lb
h
cultur
use
inocul
largevolum
cultur
next
step
omv
typic
purifi
supernat
transform
e
coli
cell
point
liter
ml
cultur
inocul
ml
starter
cultur
grown
lb
broth
c
orbit
shake
incub
rpm
reach
exponenti
phase
od
grown
bacteria
pellet
g
min
supernat
sterilefilt
millipor
express
plu
membran
filter
pe
remov
residu
bacteria
afterward
bacteria
free
supernat
concentr
ultrafiltr
use
krosflo
research
ii
tff
kda
hollow
fiber
membran
spectrum
lab
germani
final
volum
ml
result
filtrat
ml
subject
ultracentrifug
g
h
c
ti
rotor
beckman
ga
usa
separ
omv
fraction
subsequ
omv
contain
pellet
resuspend
pb
dulbecco
phosphat
buffer
salin
biochrom
gmbh
steril
filter
millexgv
syring
filter
unit
pvdf
store
c
use
amount
isol
omv
quantifi
protein
concentr
measur
use
bradford
protein
assay
enrich
omv
cultur
either
transform
empti
vector
control
mix
sd
sampl
buffer
glycerol
mm
trishcl
ph
sd
bromophenol
blue
incub
min
c
omv
sampl
separ
precast
gradient
nupag
novex
bistri
protein
gel
invitrogen
usa
subsequ
transfer
onto
immobilonfl
polyvinyliden
fluorid
pvdf
membran
merck
millipor
follow
protein
transfer
pvdf
membran
block
use
block
buffer
tb
mm
trishcl
ph
mm
nacl
contain
nonfat
dri
milk
h
room
temperatur
rt
membran
wash
min
use
wash
buffer
tbstween
mm
trishcl
ph
mm
nacl
afterward
detect
viral
protein
achiev
use
rabbit
monoclon
antibodi
recogn
influenza
viru
hemagglutinin
abcam
dilut
block
buffer
h
later
membran
wash
three
time
min
wash
buffer
next
membran
incub
dark
h
correspond
goat
antirabbit
irdy
licor
nebraska
usa
dilut
block
buffer
contain
dilut
sd
three
wash
step
min
twice
wash
buffer
tb
protein
visual
use
odyssey
infrar
imag
system
applic
softwar
packag
licor
nebraska
usa
propag
viru
inactiv
use
formaldehyd
c
h
ensur
activ
viral
particl
follow
inactiv
process
inactiv
control
vaccin
mdck
vero
cell
inocul
inactiv
strain
h
postinocul
cellcultur
supernat
test
use
either
ha
assay
plaqu
assay
merscov
volum
ml
inactiv
viral
harvest
care
layer
ml
sucros
ultracentrifug
tube
centrifug
sorval
mtx
ultracentrifug
thermo
scientif
ca
usa
rpm
h
c
pellet
resuspend
pb
requir
amount
viral
antigen
viru
mix
imject
alum
adjuv
invitrogen
ca
usa
ratio
vv
final
antigenadjuv
combin
continu
mix
min
cool
condit
effect
adsorb
antigen
surfac
adjuv
gener
optim
vaccin
formul
femal
balbc
mice
weekold
rear
suppli
anim
hous
nation
research
centr
nrc
egypt
mice
divid
group
micegroup
two
group
mice
intramuscularli
inject
omvsempti
three
group
use
control
includ
neg
control
group
inject
steril
pb
two
posit
control
group
inject
either
inactiv
inactiv
merscov
anim
receiv
booster
immun
week
serum
sampl
collect
week
prime
immun
mice
sera
separ
store
c
use
sera
collect
immunizedcontrol
mice
treat
receptordestroy
enzym
rde
vibrio
cholera
denka
seiken
tokyo
japan
kept
overnight
c
rde
inactiv
incub
c
h
dilut
sera
incub
four
ha
unit
suspens
chicken
red
blood
cell
incub
h
rt
hai
titer
reciproc
valu
dilut
agglutin
observ
titer
consid
neg
plaquereduct
neutral
test
prnt
assay
perform
determin
efficaci
stimul
antibodi
sera
vaccinatedcontrol
balbc
mice
neutral
merscov
briefli
sera
inactiv
heat
c
water
bath
min
sera
dilut
twofold
serial
dilut
dilut
fb
equal
amount
plaqu
form
unit
fb
ad
sera
dilut
serumviru
dilut
incub
c
h
humidifi
incub
co
afterward
dilut
inocul
individu
well
tissu
cultur
plate
confluent
cell
monolay
incub
c
h
plate
period
undul
everi
min
avoid
cell
dri
h
viru
adsorpt
inoculum
remov
gentli
infect
monolay
cell
wash
pb
cover
overlay
contain
mem
media
agar
penicillinstreptomycin
penstrep
plate
left
solidifi
incub
c
co
upsid
format
viral
plaqu
visibl
day
cell
monolay
fix
formaldehyd
solut
h
rt
stain
crystal
violet
solut
methanol
min
rt
wash
water
visual
plaqu
percent
inhibit
calcul
follow
plaqu
reduct
viru
control
plaqu
countsampl
plaqu
count
viru
control
plaqu
count
prnt
defin
reciproc
antibodi
dilut
requir
reduc
number
merscov
plaqu
cell
rel
control
well
eight
week
prime
immun
mice
anesthet
intraperiton
inject
ketamin
solut
dose
adjust
individu
bodi
weight
infecti
dose
tcid
influenza
viru
wild
type
administ
intranas
vaccin
control
group
ensur
full
separ
group
absenc
natur
infect
addit
control
group
five
mice
ad
subject
infect
bodi
weight
monitor
daili
mice
show
weight
loss
initi
vaccin
bodi
weight
euthan
record
dead
mice
kept
specif
pathogen
free
spf
condit
nation
research
centr
facil
unit
egypt
anim
trial
conduct
accord
recommend
guidelin
egyptian
anim
welfar
legisl
ethic
committe
nation
research
centr
egypt
approv
anim
trial
mice
approv
code
experi
infecti
viru
perform
accord
egyptian
regul
propag
influenza
virus
experi
involv
low
pathogen
highli
pathogen
avian
influenza
virus
perform
biosafeti
level
contain
cabinet
respect
approv
use
local
author
schemat
repres
figur
construct
compris
region
ncr
signal
peptid
sp
ha
gene
follow
receptorbind
domain
rbd
merscov
spike
gene
rbd
nt
amino
acid
aa
flexibl
linker
peptid
lp
gsagsag
code
sequenc
plu
ha
gene
design
link
rbd
fragment
singl
polypeptid
chain
final
fusion
protein
contain
amino
acid
aa
residu
rbd
aa
residu
lp
aa
residu
vaccin
x
peer
review
initi
bodi
weight
euthan
record
dead
mice
kept
specif
pathogen
free
spf
condit
nation
research
centr
facil
unit
egypt
anim
trial
conduct
accord
recommend
guidelin
egyptian
anim
welfar
legisl
ethic
committe
nation
research
centr
egypt
approv
anim
trial
mice
approv
code
experi
infecti
viru
perform
accord
egyptian
regul
propag
influenza
virus
experi
involv
low
pathogen
highli
pathogen
avian
influenza
virus
perform
biosafeti
level
contain
cabinet
respect
approv
use
local
author
schemat
repres
figur
construct
compris
noncod
region
ncr
signal
peptid
sp
ha
gene
follow
receptorbind
domain
rbd
merscov
spike
gene
rbd
nt
amino
acid
aa
flexibl
linker
peptid
lp
gsagsag
code
sequenc
plu
ha
gene
design
link
rbd
fragment
singl
polypeptid
chain
final
fusion
protein
contain
amino
acid
aa
residu
rbd
aa
residu
lp
aa
residu
produc
outermembran
vesicl
omv
compris
express
merscov
rbd
ha
hybrid
protein
e
coli
strain
transform
plasmid
presenc
rbd
merscov
omv
particl
examin
immunoblot
analysi
use
purifi
blot
pattern
confirm
presenc
rbdlink
ha
viral
protein
correspond
kda
kda
equal
kda
contrast
omv
isol
untransform
omvsempti
show
crossreact
protein
figur
produc
outermembran
vesicl
omv
compris
express
merscov
rbd
ha
hybrid
protein
e
coli
strain
transform
plasmid
presenc
rbd
merscov
omv
particl
examin
immunoblot
analysi
use
purifi
blot
pattern
confirm
presenc
rbdlink
ha
viral
protein
correspond
kda
kda
equal
kda
contrast
omv
isol
untransform
omvsempti
show
crossreact
protein
figur
assess
immunogen
bival
prepar
femal
balbc
mice
immun
omvsempti
comparison
inactiv
inactiv
merscov
posit
control
pb
neg
control
mice
receiv
booster
dose
three
week
prime
immun
figur
sera
collect
everi
two
week
week
two
eight
prime
immun
ncr
noncod
region
sp
signal
peptid
rbd
receptor
bind
domain
merscov
l
nucleotid
sequenc
peptid
linker
ggtagcgccggtagcgccgga
hemagglutinin
hemagglutinin
b
immunoblot
pattern
omv
extract
either
variou
controlnontransform
omv
empti
omv
antiserum
swine
antibodi
assess
immunogen
bival
prepar
femal
balbc
mice
immun
omvsempti
comparison
inactiv
inactiv
merscov
posit
control
pb
neg
control
mice
receiv
booster
dose
three
week
prime
immun
figur
sera
collect
everi
two
week
week
two
eight
prime
immun
two
week
postvaccin
mice
vaccin
inactiv
viru
reveal
increas
hai
antibodi
titer
compar
control
omvsempti
group
figur
four
week
vaccin
observ
drop
hai
titer
mice
due
booster
vaccin
week
three
interestingli
two
group
vaccin
inactiv
show
signific
increas
geometr
mean
hai
antibodi
titer
week
six
week
eight
geometr
mean
hai
antibodi
titer
decreas
respect
result
reveal
vaccin
mice
develop
strong
immunogen
respons
viru
neg
pb
control
group
omvsempti
group
hai
titer
remain
low
reflect
anim
inde
hous
influenzafre
condit
natur
infect
two
week
postvaccin
mice
vaccin
inactiv
viru
reveal
increas
hai
antibodi
titer
compar
control
omvsempti
group
figur
four
week
vaccin
observ
drop
hai
titer
mice
due
booster
vaccin
week
three
interestingli
two
group
vaccin
inactiv
show
signific
increas
geometr
mean
hai
antibodi
titer
week
six
week
eight
geometr
mean
hai
antibodi
titer
decreas
respect
result
reveal
vaccin
mice
develop
strong
immunogen
respons
viru
neg
pb
control
group
omvsempti
group
hai
titer
remain
low
reflect
anim
inde
hous
influenzafre
condit
natur
infect
addit
vaccin
mice
show
signific
increas
neutral
antibodi
merscov
strain
week
reach
highest
neutral
titer
week
eight
compar
control
group
p
figur
control
pb
inactiv
omvsempti
group
show
neutral
antibodi
merscov
eight
week
infect
figur
vaccin
x
peer
review
addit
vaccin
mice
show
signific
increas
neutral
antibodi
merscov
strain
week
reach
highest
neutral
titer
week
eight
compar
control
group
p
figur
control
pb
inactiv
omvsempti
group
show
neutral
antibodi
merscov
eight
week
infect
figur
hand
plaqu
reduct
neutral
test
use
sera
mice
vaccin
inactiv
merscov
show
complet
neutral
titer
approxim
eight
week
first
immun
activ
merscov
figur
investig
protect
level
vaccin
mice
infect
vaccinatedand
control
group
balbc
mice
week
postvaccin
figur
infect
wild
type
viru
ensur
full
separ
group
absenc
natur
infect
addit
control
group
five
mice
ad
subject
infect
group
vaccin
either
inactiv
show
weight
loss
till
day
pi
post
infect
comparison
infect
pb
control
group
interestingli
result
show
vaccin
group
inactiv
viru
protect
mice
bodi
weight
loss
bwl
figur
mortal
day
post
challeng
infect
figur
vaccin
x
peer
review
interestingli
result
show
vaccin
group
inactiv
viru
protect
mice
bodi
weight
loss
bwl
figur
mortal
day
post
challeng
infect
figur
contrast
control
group
pbstreat
mice
infect
exhibit
bwl
day
four
six
pi
result
euthanasia
figur
mortal
rate
control
group
four
day
pi
increas
gradual
day
pi
day
pi
figur
mortal
omvsempti
group
reach
day
pi
result
euthan
mice
bwl
figur
continu
evolut
swine
human
popul
recent
emerg
merscov
infect
high
mortal
rate
human
rais
awar
virus
seriou
emerg
global
health
topic
sinc
vaccin
import
strategi
combat
emerg
human
viral
infect
effect
vaccin
remain
necess
particularli
merscov
merscov
spike
protein
play
essenti
role
viru
entri
bind
antigen
rbd
region
host
cell
receptor
rbd
recogn
major
antigen
glycoprotein
fragment
induc
potent
humor
cellular
neutral
antibodi
nab
immun
respons
tradit
influenza
vaccin
produc
gener
natur
recombin
reassort
iav
express
immunogen
ha
antigen
iav
compris
two
subunit
host
antigen
site
specif
neutral
antibodi
elicit
combat
iav
strain
vaccin
natur
infect
howev
report
specif
vaccin
produc
cellcultur
embryon
egg
occasion
impair
amino
acid
aa
chang
due
seed
strain
adapt
drastic
impact
vaccin
effect
vaccin
platform
present
studi
depend
plasmidbas
bacteri
express
recombin
viral
antigen
plasmid
encod
viral
antigen
easili
quickli
modifi
insert
nonsynonym
chang
encod
region
antigen
addit
bacteri
express
lower
mutat
rate
eukaryot
platform
also
base
incorpor
combin
differ
viral
antigen
address
addit
vaccin
need
combat
season
influenza
b
virus
omv
introduc
part
novel
vaccin
formul
carri
antigen
protein
elicit
protect
respons
anim
model
divers
microorgan
n
mening
b
vibrio
cholera
salmonella
typhimurium
pseudomona
aeruginosa
gallibacterium
anati
acinetobact
baumannii
chlamydia
trachomati
shigella
spp
mycobacterium
tuberculosi
lp
outer
surfac
omv
act
selfadjuv
induc
humor
cellular
immun
therefor
omv
vaccin
may
use
without
extra
adjuv
increas
immunogen
produc
antivir
innat
immun
respons
variou
influenza
viru
infect
via
activ
macrophag
despit
exact
role
lp
context
omv
vaccin
requir
contrast
control
group
pbstreat
mice
infect
exhibit
bwl
day
four
six
pi
result
euthanasia
figur
mortal
rate
control
group
four
day
pi
increas
gradual
day
pi
day
pi
figur
mortal
omvsempti
group
reach
day
pi
result
euthan
mice
bwl
figur
continu
evolut
swine
human
popul
recent
emerg
merscov
infect
high
mortal
rate
human
rais
awar
virus
seriou
emerg
global
health
topic
sinc
vaccin
import
strategi
combat
emerg
human
viral
infect
effect
vaccin
remain
necess
particularli
merscov
merscov
spike
protein
play
essenti
role
viru
entri
bind
antigen
rbd
region
host
cell
receptor
rbd
recogn
major
antigen
glycoprotein
fragment
induc
potent
humor
cellular
neutral
antibodi
nab
immun
respons
tradit
influenza
vaccin
produc
gener
natur
recombin
reassort
iav
express
immunogen
ha
antigen
iav
compris
two
subunit
host
antigen
site
specif
neutral
antibodi
elicit
combat
iav
strain
vaccin
natur
infect
howev
report
specif
vaccin
produc
cellcultur
embryon
egg
occasion
impair
amino
acid
aa
chang
due
seed
strain
adapt
drastic
impact
vaccin
effect
vaccin
platform
present
studi
depend
plasmidbas
bacteri
express
recombin
viral
antigen
plasmid
encod
viral
antigen
easili
quickli
modifi
insert
nonsynonym
chang
encod
region
antigen
addit
bacteri
express
lower
mutat
rate
eukaryot
platform
also
base
incorpor
combin
differ
viral
antigen
address
addit
vaccin
need
combat
season
influenza
b
virus
omv
introduc
part
novel
vaccin
formul
carri
antigen
protein
elicit
protect
respons
anim
model
divers
microorgan
n
mening
b
vibrio
cholera
salmonella
typhimurium
pseudomona
aeruginosa
gallibacterium
anati
acinetobact
baumannii
chlamydia
trachomati
shigella
spp
mycobacterium
tuberculosi
lp
outer
surfac
omv
act
selfadjuv
induc
humor
cellular
immun
therefor
omv
vaccin
may
use
without
extra
adjuv
increas
immunogen
produc
antivir
innat
immun
respons
variou
influenza
viru
infect
via
activ
macrophag
despit
exact
role
lp
context
omv
vaccin
requir
investig
high
amount
lp
could
drawback
due
known
endotox
abil
induc
excess
secret
proinflammatori
cytokin
therefor
sever
ongo
investig
aim
produc
genet
detoxifi
less
reactogen
lp
improv
omv
safeti
addit
modifi
bacteri
strain
trigger
lpsrelat
immun
respons
appli
omv
product
base
observ
engin
express
antigenicallyst
immunogen
omv
base
bival
vaccin
elicit
protect
antibodi
ab
follow
immun
control
infect
merscov
recombin
construct
compris
ha
fuse
rbd
merscov
protein
express
e
coli
bacteri
strain
express
bival
antigen
incorpor
within
releas
omv
novel
chimer
produc
high
level
neutral
ab
titer
influenza
viru
week
post
immun
stimul
neutral
ab
humor
immun
togeth
lpsinduc
cellular
immun
could
fulli
protect
immun
mice
challeng
without
signific
loss
bodi
weight
surprisingli
induc
nonspecif
cellular
immun
induc
omvsempti
could
partial
protect
mice
emphas
synergist
effect
humor
cellular
immun
secret
upon
vaccin
chimer
formul
serum
transfer
experi
would
abl
elucid
role
humor
immun
independ
cellular
immun
addit
mice
demonstr
signific
increas
neutral
ab
titer
merscov
week
comparison
control
group
figur
find
ensur
omv
vaccin
platform
provid
protect
effici
neutral
invad
merscov
data
present
studi
consist
recent
report
describ
potenti
omv
biolog
activ
stabl
highli
immunogen
vaccin
protect
iav
newli
develop
recombin
omv
bear
conserv
protein
iav
effici
protect
mice
iav
challeng
studi
repres
extens
studi
suggest
gener
omv
incorpor
combin
differ
viral
antigen
gener
safe
effici
vaccin
anim
husbandri
human
summari
result
show
gener
base
vaccin
present
antigen
stabl
chimer
fusion
protein
ha
pandem
influenza
viru
strain
rbd
merscov
induc
specif
neutral
antibodi
merscov
lead
protect
immun
mice
virus
result
demonstr
omvsbas
vaccin
present
viral
antigen
potenti
vaccin
platform
provid
simultan
protect
two
differ
viral
infect
